eISSN: 3023-6940
  • Home
  • The importance of gleason score in the evaluation of bone metastasis in prostate adenocarcinoma patients whose prostate specific antigen level ≤ 20 ng / ml

Original Research

The importance of gleason score in the evaluation of bone metastasis in prostate adenocarcinoma patients whose prostate specific antigen level ≤ 20 ng / ml


1İzmir Atatürk Eğitim ve Araştırma Hastanesi,1.Üroloji Kliniği

2Manisa Merkez Efendi Devlet Hastanesi


DOI :
New J Urol. 2011; 6 (3): 11-15

Abstract

Objective: In this study, we investigated the importance of gle-ason score in detecting bone metastasis in prostate adenocarcino-ma patients whose prostate-specific antigen (PSA) level ≤ 20 ng / ml Materials and Methods: Prostate adenocarcinoma cases diago-sed by 10-quadrant transrectal ultrasound-guided prostate biopsy were divided into 2 groups of total gleason score ≤6  (30 patients) and total gleason score >6  (50 patients). Both groups compared in terms of age, total PSA and metastasis on bone scintigraphy.
Results: The mean age was 69.60 ± 6.56 in patients with gle-ason score ≤6 and 70.68 ± 8.34 in patients with gleason score > 6 (p=0.153). The mean PSA level was 12.10 ± 4.57 mg/ dl in patients with gleason score ≤ 6 and 13.11 ± 4.53 in patients with gleason score >6 (p=0.652).  There was no singnificant difference in terms of age and total PSA however metastasis on bone scintigraphy was significantly higher in the patient with gleason score>6 (p<0,001).
Conclusion: Bone scintigraphy is not used routinely in patients with prostate cancer whose PSA level ≤ 20 ng/ml for metastatic eva-luation. In this study, we detected significantly higher rate of metas-tasis on bone scintigraphy in the patient with gleason score>6 and PSA level ≤ 20 ng/ml. We suggest bone scintigraphy in prostate can-cer patients with gleason score > 6 for metastatic evaluation  even if  PSA  level  is less than or equal to  20 ng/ml.
Key Words: Prostate cancer, Gleason score, Prostate spesific antigen, Bone scintigraphy


Abstract

Objective: In this study, we investigated the importance of gle-ason score in detecting bone metastasis in prostate adenocarcino-ma patients whose prostate-specific antigen (PSA) level ≤ 20 ng / ml Materials and Methods: Prostate adenocarcinoma cases diago-sed by 10-quadrant transrectal ultrasound-guided prostate biopsy were divided into 2 groups of total gleason score ≤6  (30 patients) and total gleason score >6  (50 patients). Both groups compared in terms of age, total PSA and metastasis on bone scintigraphy.
Results: The mean age was 69.60 ± 6.56 in patients with gle-ason score ≤6 and 70.68 ± 8.34 in patients with gleason score > 6 (p=0.153). The mean PSA level was 12.10 ± 4.57 mg/ dl in patients with gleason score ≤ 6 and 13.11 ± 4.53 in patients with gleason score >6 (p=0.652).  There was no singnificant difference in terms of age and total PSA however metastasis on bone scintigraphy was significantly higher in the patient with gleason score>6 (p<0,001).
Conclusion: Bone scintigraphy is not used routinely in patients with prostate cancer whose PSA level ≤ 20 ng/ml for metastatic eva-luation. In this study, we detected significantly higher rate of metas-tasis on bone scintigraphy in the patient with gleason score>6 and PSA level ≤ 20 ng/ml. We suggest bone scintigraphy in prostate can-cer patients with gleason score > 6 for metastatic evaluation  even if  PSA  level  is less than or equal to  20 ng/ml.
Key Words: Prostate cancer, Gleason score, Prostate spesific antigen, Bone scintigraphy

Resources